Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer

Robert L. Coleman, MD, FACOG, FACS, chief medical officer of Sarah Cannon Research Institute, as well as an oncologist with Texas Oncology, a practice in The US Oncology Network, discusses an analysis of the phase 3 SORAYA trial (NCT04296890) evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine-gynx (Elahere) at different points in their disease course.

Dr Coleman on Prior Findings From SORAYA

The single-arm SORAYA trial evaluated the efficacy of mirvetuximab soravtansine in patients with folate receptor alpha–high, platinum-resistant ovarian cancer who had received 1 to 3 prior lines of therapy, Coleman says. All patients were required to have received prior bevacizumab (Avastin).

Initial findings from SORAYA showed an objective response rate (ORR) of 32.4% with mirvetuximab soravtansine and a median duration of response (DOR) of 6.9 months. An analysis of clinical responses to the agent in this trial aimed to investigate the drug’s activity and stratify response rates in patient subgroups based on how many prior lines of therapy they had received, Coleman explains. This analysis evaluated overall survival and ORR with mirvetuximab soravtansine in patients who had received the agent in the frontline setting vs in the later-line setting, Coleman notes.

Dr Coleman on ORRs With Mirvetuximab Soravtansine in Platinum-Resistant and Platinum-Sensitive Disease

Patients could have received prior bevacizumab in the frontline, platinum-sensitive, platinum-sensitive recurrent, or platinum-resistant settings. A total of 6 patients had received bevacizumab in both the platinum-resistant and platinum-sensitive settings

Of the 106 patients enrolled in SORAYA, 55 had received 3 prior lines of therapy, and 51 had received 1 or 2 prior lines. Additionally, 37% of patients had received their prior treatment in the platinum-resistant setting. All patients had received prior bevacizumab, and 16% had prior bevacizumab exposure in the platinum-resistant setting.

In the patients who received prior treatment for platinum-resistant disease, the ORR was 28.2% vs 34.8% in those who received first-line mirvetuximab soravtansine for platinum-resistant disease. In the patients who received bevacizumab in the platinum-sensitive setting, the ORR was 34.0% vs 17.6% in those who received bevacizumab for platinum-resistant disease.

Editor’s Note: Dr Coleman reports consulting positions with AstraZeneca, GSK, ImmunoGen, Novocure, OncXerna, Onconova, Epsilogen, Pfizer, Merck, Alkermes, Gradalis, Agenus, Mersana, Karyopharm, Deciphera, Roche Genentech, and Genelux; grants from Clovis Oncology, AbbVie, AstraZeneca, ImmunoGen, Seagen, and Merck; participation in independent data monitoring committees for Eisai and VBL Therapeutics; and board membership with the GOG Foundation.